This trial is evaluating whether PGV-001 will improve 1 primary outcome and 3 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 191 days.
This trial requires 27 total participants across 3 different treatment groups
This trial involves 3 different treatments. PGV-001 is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"The 5 year survival rate for prostate cancer has increased significantly since 1970. There are moderate differences between different races but race does not affect survival rates. Survival rates also vary depending on the stage of prostate cancer at the time of treatment. In general, however, prostate cancer has a very poor long-term prognosis when untreated." - Anonymous Online Contributor
"In an unselected population of Caucasian men aged 50 years or older, about 4% will develop prostate cancer at some time during their lives. About one third of these men will die within 2 years following diagnosis." - Anonymous Online Contributor
"Clinical trials are underutilized by men with prostate cancer; however, they can potentially improve outcomes for men with localized prostate cancer who were treated with watchful waiting and standard therapies." - Anonymous Online Contributor
"Most patients received only one treatment, which limits the ability to identify the most effective therapy. A substantial proportion of patients were treated with more than one or up to eight therapies. However, there was no evidence that the frequency of use of each therapy varied significantly over time. Data from a recent study highlights the need to improve the quality of care for prostate cancer by identifying the most effective therapy for specific characteristics of the disease." - Anonymous Online Contributor
"The recent development of pgv-001 has shown promise in preclinical models and has also progressed into Phase I clinical trials. Further investigations into its mechanisms of action are warranted." - Anonymous Online Contributor
"The treatment options for prostate cancer are rapidly changing. As clinicians learn more about the biology of prostate cancer, they will be better able to choose the best regimen for each individual patient. Although hormonal therapy remains the cornerstone of treatment, growing evidence suggests that other therapeutic modalities can improve the outcome of patients with advanced prostate cancer. These include radiation therapy, chemotherapy, immunotherapy, antiandrogens such as bicalutamide, and alpha-1 antitrypsin gene therapy. More research will be needed to determine whether these agents combined with hormonal therapy can yield improved outcomes in patients with advanced prostate cancer." - Anonymous Online Contributor
"Results from a recent paper showed that the drug PGV-001 administered twice per day (400 mg/day) could significantly improve the symptoms of patients suffering from BPH without worsening their general condition. However, further investigation into the mechanism of action of this drug is needed before it can be recommended for treatment use." - Anonymous Online Contributor
"It appears that prostate cancer develops from benign prostatic hyperplasia rather than being caused by exposure to a carcinogen or other environmental factor. A combination of genetic factors play an important role in determining whether these cells become malignant. However, the interaction between genetics and environmental factors is still unclear." - Anonymous Online Contributor
"Results from a recent paper was performed using the current standard of care for patients with Stage T1a [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). We were unable to demonstrate an improvement in survival rate when utilizing radical prostatectomy compared with observation alone. Patient selection based on the Gleason score and stage of the disease may have obscured a possible benefit associated with a more aggressive treatment regimen. Results from a recent paper do not support the notion that radical prostatectomy can lead to cure of prostate cancer." - Anonymous Online Contributor
"The majority of prostate cancer patients experience significant symptoms of incontinence and erectile dysfunction. A significant proportion of these patients are satisfied with their baseline QOL scores. These data suggest that an improvement in QOL can be achieved through therapy using Pgv-001." - Anonymous Online Contributor
"While there are many factors influencing the age at diagnosis of prostate cancer, it can be reliably estimated using only age and PSA level. This estimate could provide useful information to people considering prostate cancer prevention strategies." - Anonymous Online Contributor